EAGLE PHARMACEUTICALS INC (EGRX) Fundamental Analysis & Valuation

NASDAQ:EGRX • US2697961082

2.14 USD
-1.42 (-39.89%)
At close: Oct 2, 2024
2.28 USD
+0.14 (+6.54%)
After Hours: 10/2/2024, 8:06:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This EGRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to EGRX. EGRX was compared to 520 industry peers in the Biotechnology industry. While EGRX is still in line with the averages on profitability rating, there are concerns on its financial health. EGRX has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

5

1. EGRX Profitability Analysis

1.1 Basic Checks

  • EGRX had positive earnings in the past year.
  • In the past year EGRX has reported a negative cash flow from operations.
EGRX Yearly Net Income VS EBIT VS OCF VS FCFEGRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 20M 40M 60M 80M 100M

1.2 Ratios

  • EGRX has a better Return On Assets (2.99%) than 94.01% of its industry peers.
  • EGRX's Return On Equity of 4.80% is amongst the best of the industry. EGRX outperforms 94.54% of its industry peers.
  • EGRX has a better Return On Invested Capital (10.53%) than 95.77% of its industry peers.
  • EGRX had an Average Return On Invested Capital over the past 3 years of 13.59%. This is significantly below the industry average of 18.99%.
Industry RankSector Rank
ROA 2.99%
ROE 4.8%
ROIC 10.53%
ROA(3y)3.37%
ROA(5y)5.82%
ROE(3y)5.61%
ROE(5y)8.93%
ROIC(3y)13.59%
ROIC(5y)13.5%
EGRX Yearly ROA, ROE, ROICEGRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 10 20 30 40 50

1.3 Margins

  • With an excellent Profit Margin value of 4.70%, EGRX belongs to the best of the industry, outperforming 94.19% of the companies in the same industry.
  • In the last couple of years the Profit Margin of EGRX has declined.
  • EGRX's Operating Margin of 16.47% is amongst the best of the industry. EGRX outperforms 95.77% of its industry peers.
  • In the last couple of years the Operating Margin of EGRX has declined.
  • The Gross Margin of EGRX (69.86%) is better than 84.33% of its industry peers.
  • EGRX's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 16.47%
PM (TTM) 4.7%
GM 69.86%
OM growth 3Y42.71%
OM growth 5Y-1.58%
PM growth 3Y15.49%
PM growth 5Y-12.5%
GM growth 3Y0.54%
GM growth 5Y-1.58%
EGRX Yearly Profit, Operating, Gross MarginsEGRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. EGRX Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so EGRX is still creating some value.
  • Compared to 1 year ago, EGRX has more shares outstanding
  • EGRX has a worse debt/assets ratio than last year.
EGRX Yearly Shares OutstandingEGRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M
EGRX Yearly Total Debt VS Total AssetsEGRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M

2.2 Solvency

  • EGRX has an Altman-Z score of 1.81. This is not the best score and indicates that EGRX is in the grey zone with still only limited risk for bankruptcy at the moment.
  • EGRX's Altman-Z score of 1.81 is fine compared to the rest of the industry. EGRX outperforms 70.07% of its industry peers.
  • EGRX has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
  • EGRX's Debt to Equity ratio of 0.25 is on the low side compared to the rest of the industry. EGRX is outperformed by 68.84% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Altman-Z 1.81
ROIC/WACC1.32
WACC7.97%
EGRX Yearly LT Debt VS Equity VS FCFEGRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 2.16 indicates that EGRX has no problem at all paying its short term obligations.
  • EGRX has a worse Current ratio (2.16) than 75.35% of its industry peers.
  • EGRX has a Quick Ratio of 1.67. This is a normal value and indicates that EGRX is financially healthy and should not expect problems in meeting its short term obligations.
  • EGRX has a Quick ratio of 1.67. This is in the lower half of the industry: EGRX underperforms 79.58% of its industry peers.
Industry RankSector Rank
Current Ratio 2.16
Quick Ratio 1.67
EGRX Yearly Current Assets VS Current LiabilitesEGRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. EGRX Growth Analysis

3.1 Past

  • EGRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.52%.
  • EGRX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 14.81% yearly.
  • Looking at the last year, EGRX shows a decrease in Revenue. The Revenue has decreased by -5.40% in the last year.
  • EGRX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.99% yearly.
EPS 1Y (TTM)-33.52%
EPS 3Y44.53%
EPS 5Y14.81%
EPS Q2Q%-24.36%
Revenue 1Y (TTM)-5.4%
Revenue growth 3Y17.35%
Revenue growth 5Y5.99%
Sales Q2Q%-12.76%

3.2 Future

  • Based on estimates for the next years, EGRX will show a very negative growth in Earnings Per Share. The EPS will decrease by -11.47% on average per year.
  • EGRX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.24% yearly.
EPS Next Y-40.26%
EPS Next 2Y-34.69%
EPS Next 3Y-26.94%
EPS Next 5Y-11.47%
Revenue Next Year-19.31%
Revenue Next 2Y-18.72%
Revenue Next 3Y-11.22%
Revenue Next 5Y0.24%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
EGRX Yearly Revenue VS EstimatesEGRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
EGRX Yearly EPS VS EstimatesEGRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

6

4. EGRX Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 0.46, the valuation of EGRX can be described as very cheap.
  • Based on the Price/Earnings ratio, EGRX is valued cheaper than 99.82% of the companies in the same industry.
  • EGRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.83.
  • The Price/Forward Earnings ratio is 0.64, which indicates a rather cheap valuation of EGRX.
  • 99.65% of the companies in the same industry are more expensive than EGRX, based on the Price/Forward Earnings ratio.
  • EGRX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.95.
Industry RankSector Rank
PE 0.46
Fwd PE 0.64
EGRX Price Earnings VS Forward Price EarningsEGRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, EGRX is valued cheaply inside the industry as 99.12% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.31
EGRX Per share dataEGRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • EGRX's earnings are expected to decrease with -26.94% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)0.03
EPS Next 2Y-34.69%
EPS Next 3Y-26.94%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EGRX Dividend Analysis

5.1 Amount

  • No dividends for EGRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

EGRX Fundamentals: All Metrics, Ratios and Statistics

EAGLE PHARMACEUTICALS INC

NASDAQ:EGRX (10/2/2024, 8:06:00 PM)

After market: 2.28 +0.14 (+6.54%)

2.14

-1.42 (-39.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06
Earnings (Next)11-04
Inst Owners66.05%
Inst Owner Change0%
Ins Owners5.97%
Ins Owner Change0%
Market Cap27.80M
Revenue(TTM)257.50M
Net Income(TTM)12.10M
Analysts85.71
Price Target17.34 (710.28%)
Short Float %0.37%
Short Ratio0.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.91%
Min EPS beat(2)10.18%
Max EPS beat(2)17.65%
EPS beat(4)4
Avg EPS beat(4)19.72%
Min EPS beat(4)10.18%
Max EPS beat(4)29.93%
EPS beat(8)5
Avg EPS beat(8)-2.39%
EPS beat(12)8
Avg EPS beat(12)72.12%
EPS beat(16)11
Avg EPS beat(16)63.08%
Revenue beat(2)2
Avg Revenue beat(2)4.74%
Min Revenue beat(2)2.71%
Max Revenue beat(2)6.76%
Revenue beat(4)3
Avg Revenue beat(4)1.54%
Min Revenue beat(4)-7.39%
Max Revenue beat(4)6.76%
Revenue beat(8)3
Avg Revenue beat(8)-9.26%
Revenue beat(12)5
Avg Revenue beat(12)-7.18%
Revenue beat(16)5
Avg Revenue beat(16)-7.22%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 0.46
Fwd PE 0.64
P/S 0.11
P/FCF N/A
P/OCF N/A
P/B 0.11
P/tB 0.28
EV/EBITDA 1.31
EPS(TTM)4.66
EY217.76%
EPS(NY)3.34
Fwd EY155.86%
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS19.82
BVpS19.4
TBVpS7.67
PEG (NY)N/A
PEG (5Y)0.03
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 2.99%
ROE 4.8%
ROCE 13.33%
ROIC 10.53%
ROICexc 11.06%
ROICexgc 22.27%
OM 16.47%
PM (TTM) 4.7%
GM 69.86%
FCFM N/A
ROA(3y)3.37%
ROA(5y)5.82%
ROE(3y)5.61%
ROE(5y)8.93%
ROIC(3y)13.59%
ROIC(5y)13.5%
ROICexc(3y)19.91%
ROICexc(5y)21.41%
ROICexgc(3y)52.27%
ROICexgc(5y)50.12%
ROCE(3y)17.2%
ROCE(5y)17.09%
ROICexgc growth 3Y46.01%
ROICexgc growth 5Y-6.15%
ROICexc growth 3Y27.58%
ROICexc growth 5Y-11.05%
OM growth 3Y42.71%
OM growth 5Y-1.58%
PM growth 3Y15.49%
PM growth 5Y-12.5%
GM growth 3Y0.54%
GM growth 5Y-1.58%
F-Score3
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Debt/EBITDA 0.98
Cap/Depr 0.34%
Cap/Sales 0.03%
Interest Coverage 10.44
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.16
Quick Ratio 1.67
Altman-Z 1.81
F-Score3
WACC7.97%
ROIC/WACC1.32
Cap/Depr(3y)10.4%
Cap/Depr(5y)10.3%
Cap/Sales(3y)0.21%
Cap/Sales(5y)0.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.52%
EPS 3Y44.53%
EPS 5Y14.81%
EPS Q2Q%-24.36%
EPS Next Y-40.26%
EPS Next 2Y-34.69%
EPS Next 3Y-26.94%
EPS Next 5Y-11.47%
Revenue 1Y (TTM)-5.4%
Revenue growth 3Y17.35%
Revenue growth 5Y5.99%
Sales Q2Q%-12.76%
Revenue Next Year-19.31%
Revenue Next 2Y-18.72%
Revenue Next 3Y-11.22%
Revenue Next 5Y0.24%
EBIT growth 1Y-45.5%
EBIT growth 3Y67.47%
EBIT growth 5Y4.32%
EBIT Next Year-37.58%
EBIT Next 3Y-26.19%
EBIT Next 5YN/A
FCF growth 1Y-121.43%
FCF growth 3Y-2.92%
FCF growth 5Y-1.22%
OCF growth 1Y-120.96%
OCF growth 3Y-3.25%
OCF growth 5Y-2.96%

EAGLE PHARMACEUTICALS INC / EGRX FAQ

What is the fundamental rating for EGRX stock?

ChartMill assigns a fundamental rating of 4 / 10 to EGRX.


What is the valuation status of EAGLE PHARMACEUTICALS INC (EGRX) stock?

ChartMill assigns a valuation rating of 6 / 10 to EAGLE PHARMACEUTICALS INC (EGRX). This can be considered as Fairly Valued.


What is the profitability of EGRX stock?

EAGLE PHARMACEUTICALS INC (EGRX) has a profitability rating of 7 / 10.


What are the PE and PB ratios of EAGLE PHARMACEUTICALS INC (EGRX) stock?

The Price/Earnings (PE) ratio for EAGLE PHARMACEUTICALS INC (EGRX) is 0.46 and the Price/Book (PB) ratio is 0.11.


Can you provide the financial health for EGRX stock?

The financial health rating of EAGLE PHARMACEUTICALS INC (EGRX) is 3 / 10.